Literature DB >> 29980917

Intravitreal bevacizumab treatment reduces ocular blood flow in retinopathy of prematurity: a four-case report.

Tadashi Matsumoto1, Takashi Itokawa2, Tomoaki Shiba2, Masahiko Tomita2, Kotaro Hine3, Norio Mizukaki3, Hitoshi Yoda3, Yuichi Hori2.   

Abstract

PURPOSE: To evaluate the relationship between ocular blood flow, expressed as mean blur rate (MBR) by laser speckle flowgraphy, and intravitreal bevacizumab (IVB) therapy in neonates with retinopathy of prematurity (ROP).
METHODS: This was a case series study of 4 neonates with ROP under sedation before and after IVB and evaluated 8 eyes, in which the circulation could be measured three times consecutively. We performed optic nerve head blood flow measurement and fluorescein angiography (FA) before and 1 week after treatment. Blood flow was analyzed separately for MBR-A (mean of all values), MBR-V (vessel mean), and MBR-T (tissue mean). Comparisons between the MBR (-A, -V, -T), body weight, and other systemic and ocular parameters before and after treatment were performed using a paired t test.
RESULTS: The MBR values after IVB were lower than the pre-treatment values in all cases. All eyes showed leakage at neovascularization on FA before treatment. Although leakage improved 1 week after treatment, the neovascularization did not completely regress.
CONCLUSIONS: IVB improves vein dilation and artery tortuosity, while reducing ocular blood flow in neonates with ROP. We suggest that neovascularization might not be involved in reducing ocular blood flow in the early stage of IVB treatment.

Entities:  

Keywords:  Intravitreal bevacizumab; Laser speckle flowgraphy; Mean blur rate; Ocular blood flow; Retinopathy of prematurity

Mesh:

Substances:

Year:  2018        PMID: 29980917     DOI: 10.1007/s00417-018-4063-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  33 in total

1.  RETINAL BLOOD FLOW CORRELATES TO AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR IN CENTRAL RETINAL VEIN OCCLUSION.

Authors:  Yoshihisa Yamada; Kiyoshi Suzuma; Makiko Matsumoto; Eiko Tsuiki; Azusa Fujikawa; Takafumi Harada; Takashi Kitaoka
Journal:  Retina       Date:  2015-10       Impact factor: 4.256

2.  Longitudinal assessment of plus disease in retinopathy of prematurity using color Doppler imaging.

Authors:  Daniel Neely; Alon Harris; Elizabeth Hynes; Lissa McNulty; Lynne McCranor; Brent Siesky; David Plager; Derek Sprunger; Gavin Roberts
Journal:  J AAPOS       Date:  2009-10       Impact factor: 1.220

3.  Expert Diagnosis of Plus Disease in Retinopathy of Prematurity From Computer-Based Image Analysis.

Authors:  J Peter Campbell; Esra Ataer-Cansizoglu; Veronica Bolon-Canedo; Alican Bozkurt; Deniz Erdogmus; Jayashree Kalpathy-Cramer; Samir N Patel; James D Reynolds; Jason Horowitz; Kelly Hutcheson; Michael Shapiro; Michael X Repka; Phillip Ferrone; Kimberly Drenser; Maria Ana Martinez-Castellanos; Susan Ostmo; Karyn Jonas; R V Paul Chan; Michael F Chiang
Journal:  JAMA Ophthalmol       Date:  2016-06-01       Impact factor: 7.389

4.  Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.

Authors:  Jeffrey L Edelman; David Lutz; Marisol R Castro
Journal:  Exp Eye Res       Date:  2005-02       Impact factor: 3.467

5.  Color doppler imaging of the central retinal artery in premature infants undergoing examination for retinopathy of prematurity.

Authors:  D R Holland; R A Saunders; L E Kagemann; E C Bluestein; A K Hutchinson; D W Corson; A Harris
Journal:  J AAPOS       Date:  1999-08       Impact factor: 1.220

6.  Retinal VEGF levels correlate with ocular circulation measured by a laser speckle-micro system in an oxygen-induced retinopathy rat model.

Authors:  Tadashi Matsumoto; Yuta Saito; Takashi Itokawa; Tomoaki Shiba; Mari S Oba; Haruo Takahashi; Yuichi Hori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-08       Impact factor: 3.117

7.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-12

8.  Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.

Authors:  Domenico Lepore; Graham E Quinn; Fernando Molle; Antonio Baldascino; Lorenzo Orazi; Maria Sammartino; Velia Purcaro; Carmen Giannantonio; Patrizia Papacci; Costantino Romagnoli
Journal:  Ophthalmology       Date:  2014-07-04       Impact factor: 12.079

9.  Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.

Authors:  Sjakon G Tahija; Rini Hersetyati; Geoffrey C Lam; Shunji Kusaka; Paul G McMenamin
Journal:  Br J Ophthalmol       Date:  2014-01-08       Impact factor: 4.638

10.  Reproducibility of Neonate Ocular Circulation Measurements Using Laser Speckle Flowgraphy.

Authors:  Tadashi Matsumoto; Takashi Itokawa; Tomoaki Shiba; Yuji Katayama; Tetsushi Arimura; Norio Mizukaki; Hitoshi Yoda; Yuichi Hori
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

View more
  1 in total

1.  Foveal abnormalities determined by optical coherence tomography angiography in children with history of retinopathy of prematurity.

Authors:  Manami Takagi; Ichiro Maruko; Ayane Yamaguchi; Mizuha Kakehashi; Taiji Hasegawa; Tomohiro Iida
Journal:  Eye (Lond)       Date:  2019-07-04       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.